Viewpoint: Micron to Face Roughly 2 Million Shares of Forced Selling on Monday, Passive Rebalancing of Leveraged Products to Suppress South Korean Stock Market
BlockBeats News, June 7th - Leverage product researcher degentrading stated that the Hong Kong-listed leveraged fund, Southbound Double Long SK Hynix (7709.HK), due to a significant drop in the price of the South Korean stock SK Hynix last week, needed to forcibly sell about 2 million shares at the opening of the South Korean market on Monday. This sell order size is equivalent to 40% of SK Hynix's normal daily trading volume, creating huge and mechanistic selling pressure. What's more troublesome is that the leverage product's gamma effect will cause more price drops, leading to more selling pressure and potentially triggering a chain reaction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
Crypto prices
More
